Related Experiment Video

Updated: Jun 19, 2026

Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation
09:02

Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation

Published on: November 26, 2018

22.2K

Global regulatory variability in small-molecule inhibitor approvals: Differences in timelines, dosing, and pediatric

Antía Gómez-Fernández1, Alba Rubio-San-Simón2, Sae Ishimaru3

  • 1Clinical Pharmacology Department, Hospital Universitario de La Princesa, Madrid, Spain, 28006.

Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
|October 4, 2025
PubMed
Abstract

Insights

Regulatory approvals for small-molecule inhibitors show adult dosing alignment but persistent disparities in timelines and pediatric labeling across FDA, EMA, and PMDA, potentially delaying patient access to cancer therapies.

Area of Science:

  • Oncology
  • Pharmacology
  • Regulatory Science

Background:

  • Small-molecule inhibitors represent a significant advancement in cancer treatment.
  • Regulatory agencies like the FDA, EMA, and PMDA play a crucial role in drug approval and accessibility.

Purpose of the Study:

  • To compare regulatory approval processes for small-molecule inhibitors across the FDA, EMA, and PMDA.
  • To analyze differences in approval timelines, adult dosing recommendations, and pediatric labeling.

Main Methods:

  • A comprehensive review of regulatory databases for approved small-molecule inhibitors in adult malignancies.
  • Comparative analysis of drug labels to assess dosing concordance, approval dates, and pediatric indications.
  • Data extraction performed by two independent reviewers.

Main Results:

  • Fifty-five small-molecule inhibitors were approved by all three major regulatory agencies.
  • High concordance (89%) was observed in adult dosing recommendations.
  • Significant disparities were found in approval timelines (median gap of 25 months) and pediatric indications (only 27% of drugs had them).

Conclusions:

  • While adult dosing is largely harmonized, regulatory differences in approval speed and pediatric labeling persist.
  • These disparities can lead to delays in therapy availability for patients globally.
  • Harmonized multinational trials and regulatory collaboration are recommended to improve timely access and address population-specific needs.
Keywords:
Dosing harmonizationFDA-EMA-PMDA comparisonGlobal drug developmentPediatric oncology indicationsRegulatory oncology approvalsSmall-molecule inhibitors

More Related Videos

Generation of a Simplified Three-Dimensional Skin-on-a-chip Model in a Micromachined Microfluidic Platform06:30

Generation of a Simplified Three-Dimensional Skin-on-a-chip Model in a Micromachined Microfluidic Platform

Published on: May 17, 2021

4.8K
Author Spotlight: A Computational Approach to Decipher Amino Acid Preferences in Multispecific Protein-Protein Interactions06:50

Author Spotlight: A Computational Approach to Decipher Amino Acid Preferences in Multispecific Protein-Protein Interactions

Published on: January 26, 2024

2.5K

Related Concept Videos

Drug Regulation01:25

Drug Regulation

Drug regulation encompasses the management of drug usage by evaluating its safety and efficacy through assessments conducted by regulatory authorities. Regrettably, the history of drug regulation is marred by several catastrophic events. One such incident is the Elixir Sulfanilamide tragedy, in which the toxic compound diethyl glycol was included in a sweet-tasting medication, leading to numerous fatalities. This event prompted the enactment of the Food, Drug, and Cosmetic Act in 1938. Under...
Drug Products: Biologics, Biosimilars and Interchangeables01:28

Drug Products: Biologics, Biosimilars and Interchangeables

Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...
Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence01:27

Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence

Changes in polymorphic forms can significantly influence the bioavailability of poorly soluble drugs. Although the FDA defines pharmaceutical equivalence based on having the same active ingredient, dosage form, and route of administration, it does not automatically disqualify products with different polymorphic forms. This means two products with different polymorphs can still be deemed pharmaceutically equivalent. However, polymorphic differences can affect properties like wettability,...
FDA Approved Drugs: Changes to Approved Drugs01:26

FDA Approved Drugs: Changes to Approved Drugs

Post-approval, manufacturers may modify an approved new or generic drug product. Such modifications can encompass alterations in the Active Pharmaceutical Ingredient (API), manufacturing process, formulation, batch size, manufacturing site, and container closure system (FDA Guidance for Industry, April 2004). Often, a drug product may undergo multiple changes.These modifications require careful evaluation to determine their potential impact on the drug product's identity, strength, quality,...
Dosage Regimen: Individualization01:24

Dosage Regimen: Individualization

Individualization in dosing regimens is the customization of medication doses for individual patients. Its necessity arises from the goal of maximizing therapeutic benefits while minimizing risks. This approach is pivotal because human responses to drugs can vary widely; what is effective for one person may be inadequate or excessive for another. Interpatient (intersubject) variability refers to differences in drug responses between individuals, while intrapatient (intrasubject) variability...
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions01:15

Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions

PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure (CHF).